Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network (NCCN), discussed calculating value in cancer care and the dimensions of NCCN's value assessment framework, Evidence Blocks.
Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network (NCCN), discussed calculating value in cancer care and the dimensions of NCCN's value assessment framework, Evidence Blocks.
Transcript (slightly modified)
Why do we need value calculators and the value discussion in oncology today?
Value in oncology care today is a very important topic because the effectiveness of therapies but also because of the cost—both to society and to the individual patient—of the individual therapies. And so it's a circumstance where it's important to know what the consumer, what the healthcare system is getting in return for the dollar cost that is being spent on cancer care. It's very complicated and providing transparent information either by text, tables, or computer-based calculators is very important.
What are the cornerstones of NCCN's Evidence Blocks?
The NCCN Evidence Blocks are based upon 5 different dimensions of data or decision making. The first is the dimension of efficacy: how effective is the therapy? The second is safety: how safe is it to receive the therapy, what kind of difficulties or toxicities would the patient experience with the therapy? The third is that of data quality and quantity that supports the recommendation. The fourth is the consistency of the information that supports the recommendation. And the fifth is that of affordability and how affordable is the therapy to the medical system or society.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More